Rift Valley fever vaccine development, progress and constraints

Rift Valley fever vaccine development, progress and constraints

GF-TADs Meeting
January 2011

FAO Animal Production
and Health Proceedings
No. 12

Download full PDF
(470 kb - 44 pp.)

Rift Valley fever (RVF) is an acute arthropod-borne infection first recognized in Kenya in 1931. Today, the RVF virus has been found in countries across Africa, the Arabian Peninsula and islands in the Indian Ocean, including Madagascar, Comores and Mayotte. This virus has a strong capacity to spread to previously unaffected areas, thanks to its broad host range and ability to be transmitted by at least 30 different mosquito species ¿some of which are found in Europe, Australasia and the Americas. Outbreaks following first incursions of RVF can result in explosive epidemics involving both humans and livestock.

The control of RVF outbreaks includes vaccination of susceptible animals. Two vaccines are currently available; however, each has significant drawbacks. There is a widely recognized need to develop safer and more efficacious vaccines for animals. Rift Valley fever vaccine development, progress and constraints is the report of an international expert workshop that brought together leading experts and policy-makers in RVF virology, epidemiology and vaccine development. The workshop objective was to gain consensus and make recommendations on the desired features of novel veterinary RVF virus vaccines, and to explore how incentives can be established to assure that these vaccines come to market.

      Table of contents

      List of acronyms

      Past and present control of RVFV: What is needed

      View from international organizations and industry

        OIE activities and standards related to RVF
        View from the European Commission
        View from the USDA
        View from GALVmed
        View of the Animal Health Industr

      Efficacy and safety of novel candidate vaccines

        The MP-12 virus
        The Clone-13 virus
        RVFV lacking the NSs and NSm genes and DIVA
        Capripox viruses as vaccine vectors
        An avian paramyxovirus as a vaccine vector
        DNA vaccines and their combination with Modified Vaccinia Ankara vectors
        DNA vaccines and their combination with Alphavirus replicon vectors
        Virus-like particles as RVFV vaccines
        Transcriptionally-active VLPs as RVFV vaccines

      Summary discussion

        Which vaccine for where?
        The need for robust animal models
        A human RVF vaccine: all it needs is a “pull”



      List of participants

The designations employed and the presentation of material in this information product do not imply the expression of any opinion whatsoever on the part of the Food and Agriculture Organization of the United Nations (FAO) concerning the legal or development status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The mention of specific companies or products of manufacturers, whether or not these have been patented, does not imply that these have been endorsed or recommended by FAO in preference to others of a similar nature that are not mentioned. The views expressed in this information product are those of the author(s) and do not necessarily reflect the views of FAO.

ISBN 978-92-5-106921-9

All rights reserved. FAO encourages reproduction and dissemination of material in this information product. Non-commercial uses will be authorized free of charge. Reproduction for resale or other commercial purposes, including educational purposes, may incur fees. Applications for permission to reproduce or disseminate FAO copyright materials and all other queries on rights and licences, should be addressed by e-mail to [email protected] or to the Chief, Publishing Policy and Support Branch, Office of Knowledge Exchange, Research and Extension, FAO, Viale delle Terme di Caracalla, 00153 Rome, Italy.

© FAO 2011